Instead, systemic therapies—particularly chemotherapy—are typically required to control both the primary tumor and associated paraneoplastic manifestations such as SIADH or ectopic adrenocorticotropic hormone (ACTH) production. Here, POMC is linked to inappropriate ADH syndrome.